Last updated: June 10, 2026
Ethynodiol Diacetate and Ethinyl Estradiol Suppliers: API and Finished-Dose Manufacturing Sources
Ethynodiol diacetate and ethinyl estradiol are most commonly sourced as a dual-API combination for oral contraceptives (OCs). Supplier coverage typically maps to (1) API manufacturers for ethynodiol diacetate and ethinyl estradiol and (2) contract manufacturers (CMOs) that package finished-dose tablets under branded or private-label registrations.
What matters commercially
- API availability and quality: ferm power, impurity profile control, DMF support, and batch release documentation.
- Regulatory alignment: supplier ability to support Drug Master File (DMF) and/or ASMF filings for the relevant FDA DMF type.
- Scale and dossier readiness: whether the supplier can support both commercial scale and lifecycle changes (strengths, dissolution, excipients, packaging).
- IP and regulatory continuity: whether suppliers can support ANDA-ready compliance history for the relevant referencing products and formulations.
This article focuses on the supplier landscape and the sourcing paths used in practice for ethynodiol diacetate + ethinyl estradiol tablet products.
Which companies supply ethynodiol diacetate and ethinyl estradiol APIs?
API sourcing is usually handled through a small number of global intermediates-to-API routes and a wider distribution layer for ASMF/DMF holders.
Ethynodiol diacetate API supply chain: typical routes and supplier profiles
- API suppliers generally support:
- hydrogenation/acetylation-heavy synthesis history (process-specific controls),
- impurity specification management for acetate and related byproducts,
- full cGMP traceability with stability data.
- Common supplier model:
- API manufacturer supplies under DMF/ASMF,
- downstream formulation manufacturer sources API for tablet production.
Ethinyl estradiol API supply chain: typical routes and supplier profiles
- Ethinyl estradiol is an established synthetic steroid API with broader global supplier coverage than many niche steroids.
- Supplier selection is driven by:
- impurity profile and polymorph/hydrate control,
- CoA consistency and batch-to-batch comparability,
- ability to support DMF maintenance and annual reporting.
What are the finished-dose tablet manufacturers for ethynodiol diacetate and ethinyl estradiol?
Finished-dose OC tablets are typically produced by:
- the innovator/brand owner’s internal manufacturing network, or
- CMOs that support multiple oral contraceptive SKUs.
Finished-dose CMO qualification usually requires:
- documented experience with steroid OCs,
- tablet press and coating capabilities validated for high potency steroid mixes,
- containment and cleaning validation for cross-steroid contamination control,
- packaging format control (blisters, bottles) aligned to marketing authorizations.
How do DMF/ASMF API suppliers support filings for ethynodiol diacetate and ethinyl estradiol?
For US submissions, API suppliers often operate through:
- FDA Drug Master Files (DMFs), typically for drug substance manufacturing and controls.
- For outside the US, suppliers commonly file ASMF packages with the local regulators.
A DMF-capable API supplier should provide:
- manufacturing site qualification documentation,
- batch manufacturing records and method validation references,
- impurity list, synthetic route overview (restricted as applicable), and acceptance criteria,
- stability program and retest/expiry logic.
Which regional supplier groups dominate oral contraceptive steroid API and CMO capacity?
Supplier dominance for steroid OCs usually clusters by:
- Europe-based and India-based API capability,
- North America and Europe-based CMO packaging and tablet manufacturing.
Commercially, buyers structure sourcing as:
- primary supplier (commercial volume),
- secondary supplier (continuity and risk mitigation),
- optional third supplier for lifecycle changes and surge capacity.
What are the key sourcing risks for ethynodiol diacetate and ethinyl estradiol tablet supply?
Supply continuity and lead times
- Steroid APIs can have tighter seasonal demand cycles in OC markets.
- CMOs may allocate capacity based on multi-product scheduling.
Quality and impurity profile drift
- Ethinyl estradiol and ethynodiol diacetate have tight impurity requirements.
- Process changes require comparability data and regulator-facing documentation.
Regulatory and filing access
- If the API supplier does not support DMF access or the specific reference letter pathway used by a given customer, integration slows.
- Updated methods, stability, and container-closure data must align to the drug product filing.
What contract manufacturing capabilities are required for ethynodiol diacetate + ethinyl estradiol tablets?
CMOs should support:
- high-HP blending and low-dose stratification control,
- validated mixing and segregation prevention,
- tablet compression and coating for steroid stability and dissolution performance,
- packaging lines with validated cleaning and cross-product controls,
- stability chambers meeting long-term and accelerated protocols.
Typical packaging configurations
- blister packs (calendar blister variants)
- unit-dose tablets per cycle schedule
- bottle presentations with desiccant where applicable
How does supplier selection affect NDA lifecycle changes and generic entry?
Supplier changes can trigger:
- comparability work for drug product,
- bridging studies for changes in dissolution or exposure,
- regulatory amendments aligned to submitted drug product specs.
For generics/ANDAs:
- API supplier choice impacts DMF access, method equivalence, and impurity alignment.
- If the reference product has formulation-specific performance constraints, the generic needs tight dissolution matching.
How many supplier options exist for these two APIs together?
Practically, the “together” question is answered by:
- whether a single integrator can supply both APIs with coordinated DMF support, or
- whether a customer sources two separate DMF holders and manages two quality streams.
For steroid OCs, customers usually run a dual-source model for each API, then qualify combinations at the finished-dose CMO.
What is the fastest path to secure supply for ethynodiol diacetate and ethinyl estradiol?
The fastest operational path typically is:
- Buy through an established pharmaceutical ingredients distributor network that already has DMF letter access.
- Use a qualified CMO that already manufactures OC tablet dosage forms with known regulatory precedent for steroid combinations.
- Lock API DMF access and confirmed commercial batch release specs before tech transfer.
Key Takeaways
- Ethynodiol diacetate + ethinyl estradiol sourcing is dominated by DMF-capable API suppliers plus OC-focused tablet CMOs.
- Supplier selection is driven by DMF/ASMF access, impurity-control capability, and finished-dose manufacturing track record for steroid OCs.
- Commercial continuity relies on multi-supplier qualification for each API and a tablet CMO with validated cross-product controls and packaging readiness.
FAQs
1) Who typically holds the FDA DMF for ethinyl estradiol APIs used in contraceptive tablets?
DMF holders are usually API manufacturers that file drug substance manufacturing and controls under the relevant DMF type and grant reference rights to customers.
2) What does a qualifying API supplier need to provide for ethynodiol diacetate?
The supplier must provide DMF/ASMF documentation, impurity specs, method validation summaries, stability data, and controlled change-management support.
3) How do API changes impact finished-dose stability for ethynodiol diacetate + ethinyl estradiol tablets?
Impurity drift, particle size differences, and excipient interactions can shift dissolution and exposure, requiring comparability and sometimes bridging work.
4) Are blister and bottle packaging lines treated differently for these OC tablet products?
Yes. Packaging validation, desiccant logic (where applicable), and blister seal integrity programs differ.
5) What supplier model reduces risk in oral contraceptive supply?
A dual-source approach for each API plus a qualified CMO with experience in high-potency steroid tablet manufacturing.
References (APA)
No sources were provided in the prompt to support a supplier-company list with verifiable citations.
